Effects of bariatric surgery on non-invasive markers of MASLD: a retrospective analysis.
4 affiliations
- 1Department of Gastroenterology, Tidal Health Peninsula Regional, Salisbury, MD, USA.
- 2Department of Internal Medicine, Tidal Health Peninsula Regional, 100 East Carroll Street, Salisbury, MD, 21801, USA. [email protected].
- 3Department of Internal Medicine, Tidal Health Peninsula Regional, 100 East Carroll Street, Salisbury, MD, 21801, USA.
- 4Department of Gastroenterology & Hepatology, Mercy Medical Center, University of Maryland School of Medicine, Baltimore, USA.
Abstract
Introduction
MASLD is common form of chronic liver disease leading to cirrhosis and liver cancer. This study evaluated the impact of bariatric surgery on the progression of MASLD.Methods
This was a retrospective study of 181 patients undergoing weight loss surgery (sleeve gastrectomy (SG = 54) or Roux-en-Y gastric bypass (RGB = 127) at TidalHealth, Salisbury, MD from 2017 to 22. Non-invasive markers of fibrosis: FIB-4, MASLD Fibrosis Score (MFS), and BARD were assessed at baseline and 12-18 months post-op. Change in fibrosis was assessed using the paired t-test.Results
Baseline demographics, including BMI, AST, ALT, platelet count, and comorbidities (diabetes, hypertension), are presented in Table 1. Pre- and post-op changes in non-invasive fibrosis scores are summarized in Table 2. The majority of the included patients (127) underwent gastric bypass (70.2%); whereas 54 patients underwent a gastric sleeve procedure (29.8%). Mean change in BMI was 46.2 to 37.8 (p < 0.001). A statistically significant reduction in the mean MFS (0.205 to -0.373, p = 0.0001; 95% CI: 0.28 to 0.87) was observed, indicating a shift in fibrosis scores from the indeterminate to the low-risk fibrosis category for the entire cohort. In a subgroup of 25 patients with advanced baseline fibrosis (FIB-4 > 1.4[2] ), bariatric surgery resulted in a significant reduction in MFS from 1.63 to 0.84 (p = 0.001), indicative of meaningful score-based improvement in estimated fibrosis risk. In a subgroup of patients with advanced fibrosis at baseline (n = 25 patients), the drop in BARD score was statistically significant (3.48 to 3.28; p = 0.05). The FIB-4 score showed a modest but statistically significant increase in the overall cohort (0.95 to 1.02; p = 0.004), and remained essentially unchanged in the advanced fibrosis subgroup (1.94 to 1.92; p = 0.80), highlighting the limitations of this index for longitudinal monitoring.Conclusion
Bariatric surgery resulted in significant improvement in non-invasive fibrosis scores of MASLD, as shown by reduction in the MFS and BARD scores in the group with advanced fibrosis. Changes in the FIB-4 scores were less consistent, suggesting this test is less useful for longitudinal assessment of fibrosis in patients with MASLD and is better suited as a screening tool.
Related
- Negative Appendicectomy Rate and Surgery Despite Negative Triple-Screen Inflammatory Markers in Children: A Single-Centre Retrospective Cohort Study
- Nutritional and Metabolic Trajectories up to 10 Years After Metabolic and Bariatric Surgery: A Tertiary-Centre Retrospective Longitudinal Cohort Study
- Implementation of a Structured Perioperative Checklist-Based Standardization Process and Early Postoperative Outcomes After Bariatric Surgery: A Single-Center Retrospective Pre–Post Cohort Study
- The Reported Prevalence of Micronutrient Deficiency after Metabolic Bariatric Surgery and Adherence to British Obesity and Metabolic Specialist Society Nutritional Guidelines: A Multicentre Retrospective Cohort Study
- Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD
BibTeX
@article{lukolic2026effects,
title = {{Effects of bariatric surgery on non-invasive markers of MASLD: a retrospective analysis.}},
author = {Ismet Lukolic and Junaid Khan and Michael McCabe and Muhammad Jibran and Mohammad Hamza and Rajoana Rojony and Safana Ismail and Dhruvkumar Patel and Anurag Maheshwari},
journal = {BMC gastroenterology},
year = {2026},
month = jul,
doi = {10.1186/s12876-026-05187-5},
url = {https://europepmc.org/article/MED/42958058},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Effects of bariatric surgery on non-invasive markers of MASLD: a retrospective analysis.
AU - Ismet Lukolic
AU - Junaid Khan
AU - Michael McCabe
AU - Muhammad Jibran
AU - Mohammad Hamza
AU - Rajoana Rojony
AU - Safana Ismail
AU - Dhruvkumar Patel
AU - Anurag Maheshwari
PY - 2026
DA - 2026/07/31
JO - BMC gastroenterology
DO - 10.1186/s12876-026-05187-5
UR - https://europepmc.org/article/MED/42958058
AB - Introduction MASLD is common form of chronic liver disease leading to cirrhosis and liver cancer. This study evaluated the impact of bariatric surgery on the progression of MASLD.Methods This was a retrospective study of 181 patients undergoing weight loss surgery (sleeve gastrectomy (SG = 54) or Roux-en-Y gastric bypass (RGB = 127) at TidalHealth, Salisbury, MD from 2017 to 22. Non-invasive markers of fibrosis: FIB-4, MASLD Fibrosis Score (MFS), and BARD were assessed at baseline and 12-18 months post-op. Change in fibrosis was assessed using the paired t-test.Results Baseline demographics, including BMI, AST, ALT, platelet count, and comorbidities (diabetes, hypertension), are presented in Table 1. Pre- and post-op changes in non-invasive fibrosis scores are summarized in Table 2. The majority of the included patients (127) underwent gastric bypass (70.2%); whereas 54 patients underwent a gastric sleeve procedure (29.8%). Mean change in BMI was 46.2 to 37.8 (p < 0.001). A statistically significant reduction in the mean MFS (0.205 to -0.373, p = 0.0001; 95% CI: 0.28 to 0.87) was observed, indicating a shift in fibrosis scores from the indeterminate to the low-risk fibrosis category for the entire cohort. In a subgroup of 25 patients with advanced baseline fibrosis (FIB-4 > 1.4[2] ), bariatric surgery resulted in a significant reduction in MFS from 1.63 to 0.84 (p = 0.001), indicative of meaningful score-based improvement in estimated fibrosis risk. In a subgroup of patients with advanced fibrosis at baseline (n = 25 patients), the drop in BARD score was statistically significant (3.48 to 3.28; p = 0.05). The FIB-4 score showed a modest but statistically significant increase in the overall cohort (0.95 to 1.02; p = 0.004), and remained essentially unchanged in the advanced fibrosis subgroup (1.94 to 1.92; p = 0.80), highlighting the limitations of this index for longitudinal monitoring.Conclusion Bariatric surgery resulted in significant improvement in non-invasive fibrosis scores of MASLD, as shown by reduction in the MFS and BARD scores in the group with advanced fibrosis. Changes in the FIB-4 scores were less consistent, suggesting this test is less useful for longitudinal assessment of fibrosis in patients with MASLD and is better suited as a screening tool.
SN - 1471-230X
ER -